Radio Waves Ignite Hope: NeuroEM's Bold Leap in Alzheimer's War
- NeuroEM Therapeutics secures $1.33 million, fueling its mission to commercialize a drug-free Alzheimer's treatment.
- Pioneering TEMT-RF technology aims to reverse cognitive decline using a non-invasive, at-home wearable device.
- Seasoned tech investor Jamie Rutledge joins NeuroEM's board, bolstering strategic efforts.
In a world desperate for a breakthrough against the relentless shadow of Alzheimer's disease, a beacon of hope emerges. NeuroEM Therapeutics®, an award-winning pioneer, has just supercharged its quest, closing initial rounds of $1.33 million in a $5 million equity raise. This vital infusion, led by BlueLake.vc, propels the company's revolutionary drug-free approach towards commercial reality, promising to combat cognitive decline not just from Alzheimer's but other neurodegenerative diseases3, 4.
At the heart of this battle is NeuroEM's groundbreaking Transcranial Electromagnetic Treatment (TEMT-RF) technology. Born from an unexpected lab discovery5, this patented system uses radio frequencies to target and potentially reverse the very damage Alzheimer's inflicts, aiming to break down toxic proteins like beta-amyloid and tau tangles1, 3. "BlueLake's support demonstrates the importance of maintaining our momentum," declared Dr. Gary Papageorgiou, CEO of NeuroEM Therapeutics. "It fuels the tireless efforts...to restore the hope and dignity Alzheimer's disease has already stolen from millions."
The company's first weapon in this fight, the MemorEM device—a lightweight cap designed for at-home use—has shown extraordinary promise. Worn for an hour twice daily, it delivers specific ultra-high frequencies, a non-invasive treatment that has already earned FDA Breakthrough Device status2, 3.
Joining this critical mission is Jamie Rutledge of BlueLake.vc, now a member of NeuroEM's Board of Directors. A veteran technology investor with deep expertise from Dyson and Lenovo, Rutledge hailed NeuroEM's approach as "transformative, defensible, and grounded in scientific rigor." He added, "This approach to drug-free treatment and prevention of Alzheimer's holds tremendous promise in tackling a disease that has eluded effective solutions for decades."
With Alzheimer's affecting half a million Americans annually and no cure in sight1, 3, NeuroEM's charge offers a new front in this devastating war, aiming to extend healthy longevity for millions. To learn more, visit [website].
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.